MentionFox
Home › Stakes › Ascendis Pharma A/S
5%+ stakes · Schedule 13D and 13G

Ascendis Pharma A/S: 5%+ holders

Who has reported owning 5% or more of Ascendis Pharma A/S, from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more4
Filings13
Latest filing2026-08-13

Ascendis Pharma A/S has 13 Schedule 13D or 13G filings on record since 2025-08-13. 4 holders' latest filing reports 5% or more of ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
T. Rowe Price Investment Management, Inc.10.5%6,506,219SCHEDULE 13G/A, 2026-05-072026-04-30
Westfield Capital Management Company, L.P.8.48%5,185,696SCHEDULE 13G/A, 2026-02-112025-12-31
Fmr LLC6.6%3,852,101SCHEDULE 13G/A, 2026-05-062026-03-31
Janus Henderson Group Plc6%3,719,452SCHEDULE 13G/A, 2026-05-152026-03-31
Artisan Partners Asset Management Inc.4.2%2,634,024SCHEDULE 13G/A, 2026-08-132026-06-30
Capital International Investors3.2%2,013,285SCHEDULE 13G/A, 2026-05-142026-03-31

Timeline

FiledHolderPercentFiling
2025-08-13Capital International Investors5.6%SCHEDULE 13G
2025-08-14Janus Henderson Group Plc8%SCHEDULE 13G/A
2025-08-14T. Rowe Price Investment Management, Inc.6.4%SCHEDULE 13G/A
2025-11-14Janus Henderson Group Plc7.8%SCHEDULE 13G/A
2025-11-14T. Rowe Price Investment Management, Inc.4.8%SCHEDULE 13G/A
2026-02-03Artisan Partners Asset Management Inc.5.2%SCHEDULE 13G/A
2026-02-11Westfield Capital Management Company, L.P.8.48%SCHEDULE 13G/A
2026-05-06Fmr LLC6.6%SCHEDULE 13G/A
2026-05-07T. Rowe Price Investment Management, Inc.9.9%SCHEDULE 13G
2026-05-07T. Rowe Price Investment Management, Inc.10.5%SCHEDULE 13G/A
2026-05-14Capital International Investors3.2%SCHEDULE 13G/A
2026-05-15Janus Henderson Group Plc6%SCHEDULE 13G/A
2026-08-13Artisan Partners Asset Management Inc.4.2%SCHEDULE 13G/A

Tools for this story

Each opens in a new tab, filled in for Ascendis Pharma A/S. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/ascendis-pharma-a-s
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Ascendis Pharma A/S 5%+ holders: 4 at 5% or more, largest T. Rowe Price Investment Management, Inc. 10.5%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/ascendis-pharma-a-s